Replies to post #17533 on DNAprint Genomics (DNAG)

[DorseyE]

Ditto mingwan0, not many see the IBM/Moffitt/AFFX/DNAP deal coming!!!

[Gcbr]

Ming---I like this.


generation21 –
a face to the biotechnology give
Peter Pohl

Pioneers enter new ground – and exactly that my brothers and I have as enterprise founders of the GATC Biotech AG before 12 years getan.– As exempt private companies we are active in one of the most dynamic and most promising industries of the world: the biotechnology. We understand ourselves as market leaders for integrated molecular-biological services, which we offer to our customer from academy and industry world-wide. Within the Biotech scene GATC is however not well-known naturally, outside of the industry.

Here the goal attaches on and the purpose of the generation21 –– without statute, managing director and two-day federation meetings. Together with ten further enterprises from the ranges of the red and green biotechnology in Germany we created this initiative. We would like to represent which we make, who we are, how we work and for which it goes. We can fall back to our completely personal experiences. We look for the dialogue outward. We want to speak with the citizens, in order to explain our research and to clarify the use of the biotechnology. For example in a firm group of interested citizens in Berlin, who discuss openly with us chances and risks. Their opinions are reported in the WORLD and continued to discuss: What brings us the biotechnology? Information on our health insurance company maps to it to lead that the cashes prescribe us, how we to live will be supposed? Where does the use for us lie in the new technologies? Is genetically manufactured food now injurious to health or not?

In addition we look for the dialogue on meetings, where specialists do not only discuss. For example on the Oekomeni church conference in Berlin or with current fairs to consumer questions. The public is to have the chance to experience more from humans and over humans who engage themselves in the biotechnology enterprises for new solutions. This task can decrease in the long run nobody to us, because we would like to give a face to the abstract term biotechnology.

Everyone of us makes its time available despite the strained situation as a managing director, in order to make the generation21 well-known. Our initiative consists particularly of recent and still small Biotech enterprises, which carry a large part out of the research and development. For example with cancer: New methods of analysis and diagnostics methods will enter many more individually with the patients. That will revolutionize the health system umkrempeln and. Before it some humans have fear, keyword: Glaeserner patient. And indeed carefully consideration must be taken on personality rights, but which disturbs us is that hardly someone speaks about the new chances! Over fewer side effects, over?gesuendere“, more careful ways of treatment. Of it we are not at all so far.

We need a clear politico-economic route of march. It cannot be that Ministry promotes our technology and it out-brakes another. Or however that the European Union bio patent guideline was not converted after four years yet into national right. Straight ones with small enterprises are often patent rights the none?Vermoegensgegenstaende“ it at all have. Without sufficient patent protection small enterprises of investors get neither money, nor they can lock contracts with large Pharmafirmen.

For the biotechnology, which is no longer only one key technology, but to the engine for the entire economy will could, arrives it now on a broad support. Humans are not to have been able a fear of a new technology, but confidence into their solutions. In the AIDS therapy for example the print applies “gentechnologisch hergestellt“ on some new products in the meantime as the highest quality seal. Politics, economics and science could take up that and pursue finally with us a common goal: Raus from the wasteland shank! Germany must in the biotechnology world-wide to the point.

Members of the generation21:

Joern Aldag, chairman of the board of the Evotec OAI AG

Dr. Dr. Andreas Barner, stellv. chairmen of the board of the federation of searching medicament manufacturers e.V.,
Director/conductor of the division Pharma research, development and medicine, Boehringer Ingelheim

Thomas's small, joint founder and executive committee of the Noxxon Pharma AG

Dr. Arno J. Krotzky, Geschaeftsfuehrer metanomics of the GmbH & Co.KGaA

Professor Dr. Hermann Luebbert, chairman of the board of the Biofrontera Pharmaceuticals getting thing AG

Dr. Klaus mark-hit a corner, Chief Financial Officer of the biogenous ix AG

Dr. Simon E. Moroney, Vorstandsvorsitzender of the MorphoSys AG

Peter Pohl, Mitgruender and Chief Executive Officer of the GATC Biotech AG

Dr. Claudia Ulbrich, acting Gesellschafterin of the LipoNova GmbH

Dr. Sabrina wagner, business guide greenovation of the Biotech GmbH

Dr. Stefanie Waschuetza, chairman of the board of the AdnaGen AG

Professor Stadler, chairman of the German industrial combination biotechnology




Take Care
Arch

[ifida]

mingwan0.....thanks for the info....

The neurogenetics section at the chair of animal physiology produces transgenic animal models and uses them to investigate the function of pharmacologically and medically relevant genes. The chair interacts closely with Biofrontera Pharmaceuticals GmbH, a biotech company founded by Prof. Lübbert. This allows to make full use of the synergies resulting from such a collaboration and it gives students insight into the requirements and working style of academic as well as private research institutions. The goal of the projects is to understand the pathophysiological mechanisms of diseases of the nervous system.

The neurogenetics section comprises three projects:

1) The investigation of a neurotransmitter system which modulates the basic activity of the nervous system. The transmitter is called serotonin (the chemical name is 5-hydroxytryptamine) since it was discovered as a substance in the serum that causes blood vessel contraction. Serotonin has 14 different receptor types mediating variable functions of the transmitter. At the chair of animal physiology we investigate most actively the 5-HT2 receptor group which causes calcium release into the cytoplasm. Functions of this receptor group comprise the regulation of appetite and anxiety states, as well as the initiation of migraine attacks. The question investigated is how these receptors interact with other members of the signal cascade. Genetically modified mice are used to address this problem (participating research group: Dr. X. Zhu).

2) The pathophysiological mechanism of inherited forms of Parkinson’s disease. In collaboration with Biofrontera transgenic animal models for Parkinson’s diseases were established. Mutations had been described in humans which cause an early-onset form of Parkinsonism. These mutations were introduced into the genome of mice. The animals are characterised using neuroanatomical and behavioural approaches. Biofrontera investigates the animals using its patented DEPD® technology to monitor gene expression changes. These investigations should give insight into the pathological processes and their temporal progression, allowing conclusions about the cascade of events which eventually leads to the degeneration of dopaminergic neurons (participating research groups: Dr. C. Stichel-Gunkel, Dr. X. Zhu).

3) The pathophysiological mechanism of inherited forms of blindness. Some cases of blindness have an inherited origin. One of the genes that can be responsible is the so-called ABCR-Gene which encodes a protein with unknown function. How a defect in this gene triggers a pathological process resulting in a degeneration of the retina is also not known. To investigate this problem, a mutation is introduced into the mouse genome which in an almost identical form occurs in human patients. The consequences of the mutation for the development, function, survival and aging of retinal cells are investigated (participating research group: Dr. M. Andriske).